Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06747775 in Advanced EGFR-Mutant NSCLC
NCT02349633Phase 2Terminated
- Sponsor
- Pfizer
- Start
- May 2015
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of mavelertinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started May 2015; status: terminated.
02
Drugs
mavelertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02349633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349633.